Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Histone Deacetylase Inhibitor, MS-275 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Histone Deacetylase Inhibitor, 3 mg | EXPERIMENTAL | Subjects received 3 mg MS-275 orally biweekly (Days 1 and 15 of a 4 week cycle) or until disease progression or unacceptable toxicity |
| Histone Deacetylase Inhibitor, 7 mg | EXPERIMENTAL | Subjects received 7 mg MS-275 orally weekly (Days 1, 8, and 15 of a 4 week cycle) until disease progression or unacceptable toxicity |
| Name | Type | Description |
|---|---|---|
| Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894) | DRUG | MS-275, 3 mg on Days 1 and 15 of a 4-week cycle |
Inclusion Criteria: * Adult subjects with Stage III or IV non-resectable nonuveal (cutaneous or mucosal) metastatic melanoma who had received at least one but no more than two previous systemic therapies (immunotherapy and/or chemotherapy) for metastatic disease and who had not responded to or who ...
Top 20 of 50 competitors